Prime Therapeutics Links Medical and Pharmacy Benefits to Tame Specialty Drug Costs

Specialty pharmacy has become the single most important line item for employers and insurers managing drug spend, and the trend shows no sign of reversing. A recent study from the Pharmaceutical Strategies Group found that 43% of employers and benefit leaders rank specialty pharmacy spend management as a top goal. The pressure is building from the supply side too. Specialty drugs account for roughly half of the pharmaceutical development pipeline, but they represented 76% of novel drugs approved by the FDA in 2025.

Against that backdrop, Blues-backed PBM Prime Therapeutics used its annual Specialty Summit last month to push a thesis that's gaining traction across the industry: the wall between medical and pharmacy benefits is a structural liability, not a neutral administrative boundary.

Mostafa Kamal, Prime's CEO, framed the issue in patient terms. People living with complex conditions don't experience their care through the lens of separate benefit categories, so the management of that care shouldn't be split that way either. The stakes are larger than they might appear on paper. Kamal noted that roughly half of all specialty pharmacy spend actually sits within the medical benefit, not the pharmacy benefit, a reflection of how complex these therapies and the conditions they treat have become.

"We believe if you're not managing specialty in an integrated way, you're not really managing specialty," Kamal said.

Why Integration Is the Differentiator

Prime's bet on integration has a clear origin point: its 2022 acquisition of Magellan Rx. That deal gave the company a foundation to build cross-benefit capabilities, and Prime has layered additional initiatives on top of it in the years since. Ownership structure matters here too. The PBM is jointly owned by 19 Blue Cross Blue Shield plans, giving it access to medical benefits data that a standalone pharmacy player wouldn't have.

George Van Antwerp, Prime's senior vice president of product innovation and strategy, argued that making this work requires a mental shift inside the company itself. During a conference session, he described moving away from viewing specialty pharmacy purely as a dispensary function and toward treating it as a node in a broader care coordination network. That shift is easier to execute when the financial incentives support it.

Prime's economic model isn't tied to fulfillment. That detail matters more than it might seem. It frees the company to recommend whichever dispensing channel is most efficient for a given patient, rather than defaulting to its own pharmacy because that's where the revenue sits.

The company's IntegratedRx program is a practical expression of that model. It lets patients fill certain prescriptions either at an in-house pharmacy or directly at their doctor's office, with the provider and pharmacist communicating directly to coordinate care. The program currently covers medications for cystic fibrosis and oncology, two categories where treatment complexity and cost concentration are both high.

The early results are notable. Prime reports a 9% reduction in total cost of care through IntegratedRx, alongside a 95% patient satisfaction rate, with respondents reporting they were either satisfied or very satisfied with their experience. Van Antwerp said the structural point is simple: if a particular pharmacy or fulfillment channel is "right, cost-effective, clinically appropriate," Prime can shift toward it without internal resistance, because it isn't incentivized to fill the prescription itself.

Stephen Cutts, Prime's chief clinical and specialty officer, pointed to the financial concentration driving urgency around this work. About 3% of patients account for roughly 60% of spending within the pharmacy benefit alone. Widen the lens to include the medical benefit, and between 10% and 13% of patients drive more than 90% of total drug costs.

"You're talking about an increasingly concentrated group of patients that are driving a disproportionate amount of drug spend, and there's an incredible amount of complexity that's needed in order to be able to deliver a more personalized care experience for those patients," Cutts said.

That concentration creates both risk and opportunity. A single high-cost patient population drives outsized spend, meaning even modest improvements in care coordination can produce measurable savings at scale. Cutts cited a common clinical scenario: a patient who begins therapy in a hospital setting and later wants to transition to self-administration at home. Managing that handoff well requires visibility into both medical and pharmacy data simultaneously, something siloed systems struggle to provide.

Prime's existing relationships with multiple BCBS plans give it a structural advantage in executing this kind of transition management, according to Cutts. The PBM can draw on medical benefits data from its owner plans directly, rather than negotiating data access as an outside vendor would.

"We're more of an orchestrator that is able to help make sure that the patient can get that needed medication at the right site of care that's more convenient and cost-effective," Cutts said. "I would say that this is a huge opportunity, not just today but increasingly in the future."

The Bottom Line

Prime's integration push is a credible response to a real structural problem, and the early IntegratedRx numbers, a 9% total cost reduction and 95% patient satisfaction, offer tangible proof points rather than aspirational marketing. The company's ownership structure and fulfillment-agnostic economics give it a genuine edge that competitors without similar PBM-health plan alignment will struggle to replicate quickly. The risk for investors and industry watchers is scale: IntegratedRx currently covers two therapeutic categories, cystic fibrosis and oncology, out of a far larger specialty landscape. Whether the model extends cleanly to other high-cost conditions, and whether the cost savings hold up as patient volumes grow, will determine if this is a durable competitive advantage or a well-executed pilot. Given that 10% to 13% of patients drive over 90% of total drug costs across both benefits, the addressable opportunity is substantial, but so is the execution risk in managing that population well.